X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs STRIDES SHASUN LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA STRIDES SHASUN LTD DISHMAN PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 25.1 14.4 174.4% View Chart
P/BV x 3.3 1.9 172.0% View Chart
Dividend Yield % 0.7 0.5 124.1%  

Financials

 DISHMAN PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
STRIDES SHASUN LTD
Mar-16
DISHMAN PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs3741,413 26.5%   
Low Rs129848 15.2%   
Sales per share (Unadj.) Rs197.8353.3 56.0%  
Earnings per share (Unadj.) Rs21.223.4 90.7%  
Cash flow per share (Unadj.) Rs34.741.0 84.7%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.80.4 179.7%  
Book value per share (Unadj.) Rs179.9320.4 56.1%  
Shares outstanding (eoy) m80.6989.35 90.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.33.2 39.8%   
Avg P/E ratio x11.948.3 24.6%  
P/CF ratio (eoy) x7.227.6 26.3%  
Price / Book Value ratio x1.43.5 39.7%  
Dividend payout %9.421.4 44.1%   
Avg Mkt Cap Rs m20,306100,988 20.1%   
No. of employees `0000.84.7 17.7%   
Total wages/salary Rs m5,3554,988 107.3%   
Avg. sales/employee Rs Th19,252.76,730.0 286.1%   
Avg. wages/employee Rs Th6,459.51,063.6 607.3%   
Avg. net profit/employee Rs Th2,064.1445.5 463.3%   
INCOME DATA
Net Sales Rs m15,96131,564 50.6%  
Other income Rs m2651,212 21.9%   
Total revenues Rs m16,22632,776 49.5%   
Gross profit Rs m4,1035,213 78.7%  
Depreciation Rs m1,0911,573 69.3%   
Interest Rs m9441,803 52.4%   
Profit before tax Rs m2,3343,049 76.5%   
Minority Interest Rs m0127 0.0%   
Prior Period Items Rs m1-27 -4.1%   
Extraordinary Inc (Exp) Rs m0-371 0.0%   
Tax Rs m624689 90.6%   
Profit after tax Rs m1,7112,089 81.9%  
Gross profit margin %25.716.5 155.7%  
Effective tax rate %26.722.6 118.3%   
Net profit margin %10.76.6 162.0%  
BALANCE SHEET DATA
Current assets Rs m11,01835,949 30.6%   
Current liabilities Rs m9,51719,402 49.1%   
Net working cap to sales %9.452.4 17.9%  
Current ratio x1.21.9 62.5%  
Inventory Days Days11071 155.8%  
Debtors Days Days35127 27.5%  
Net fixed assets Rs m16,30434,478 47.3%   
Share capital Rs m161894 18.1%   
"Free" reserves Rs m12,90722,601 57.1%   
Net worth Rs m14,51628,632 50.7%   
Long term debt Rs m4,18927,455 15.3%   
Total assets Rs m29,80576,591 38.9%  
Interest coverage x3.52.7 129.0%   
Debt to equity ratio x0.31.0 30.1%  
Sales to assets ratio x0.50.4 129.9%   
Return on assets %8.95.1 175.3%  
Return on equity %11.87.3 161.5%  
Return on capital %17.58.2 214.6%  
Exports to sales %24.848.1 51.5%   
Imports to sales %3.714.5 25.8%   
Exports (fob) Rs m3,95615,192 26.0%   
Imports (cif) Rs m5964,565 13.1%   
Fx inflow Rs m4,95216,612 29.8%   
Fx outflow Rs m6975,292 13.2%   
Net fx Rs m4,25511,320 37.6%   
CASH FLOW
From Operations Rs m2,786717 388.8%  
From Investments Rs m-1,529-22,284 6.9%  
From Financial Activity Rs m-94129,488 -3.2%  
Net Cashflow Rs m3168,073 3.9%  

Share Holding

Indian Promoters % 61.4 27.7 221.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 37.8 9.8%  
FIIs % 12.7 8.6 147.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 25.9 85.3%  
Shareholders   46,261 56,241 82.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  FRESENIUS KABI ONCO.  J.B.CHEMICALS  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Flat Finish to the Week; Cadila Healthcare Rallies 7%(Closing)

Indian share markets finished marginally higher for the week in a thin trade amid buying in pharma stocks, software stocks and capital good stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - WYETH LTD COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS